Harvard's headache cure: LSD?
» More ways to bookmark this page
Boston Business Journal coverage of John Halpern's move to introduce a BOL-148
variant as a cluster headache treatment.
Move over, Advil. A Harvard Medical School researcher says LSD, the hallucinogen at the heart of the 1960s drug counterculture, holds a better treatment for humanity's worst headaches.
Harvard researcher John Halpern has formed a company he hopes will bring to market a drug based on his research into the effects of lysergic acid diethylamide on cluster headaches, a rare but devastating condition that is as bad as it sounds.
Halpern, a noted expert in the long-term effects of drug use, said research suggests chemicals present in LSD are an astonishingly effective cure for cluster headaches. His company, Entheogen Corp., is seeking $10 million to bring the drug through to FDA approval, according to a regulatory filing this week.
Entheogen's drug does not cause triptastic visions, Halpern said. It is based on BOL-148, a non-hallucinogenic LSD derivative developed in the 1950s and 60s for research into the effects of LSD on the brain, when such was last in vogue. "Trying to do a double-blind, placebo-controlled trial with a drug that's as psychoactive as LSD is impossible," Halpern explained.
[EDITOR'S NOTE: We are no longer accepting anonymous comments on this post. If you have something to say about this issue, it must be on the record as an actual person. Thank you. If you use a false name, handle, or are not logged in as an identified user, your comment will be deleted.]